Translational Pharmacology

UB’s New York State Center of Excellence in Bioinformatics & Life Sciences (CBLS) has established the interdisciplinary TPRC within its developing research infrastructure. To date, TPRC has received funding from the National Institutes of Health, including:

• National Institute of Allergy and Infectious Diseases (NIAID)
• National Institute on Drug Abuse (NIDA)
• National Institute of Mental Health (NIMH)
• National Center for Advancing Translational Sciences (NCATS)
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• NIH Fogarty International Center

TPRC is designed to foster collaboration and advance innovation at multiple stages of drug development, including:

• Discovery
• Pre-clinical evaluation
• Phase I, II, and III FDA trials 
• Ongoing post-approval Phase IV research
• Nanomedicine

The core’s work is wide-ranging, but emphasizes:

• Oncology
• Neurology
• Infectious disease 
• Cardiovascular disease 
• Inflammation and immunosuppression

Contributing to the development of new therapeutics, diagnostics and devices is a central goal of the program, which works with corporate partners to foster the goals of commercialization and regional economic development.

• Core laboratory facility for bioanalysis and drug development
• Healthcare informatics and medication management research network
• Translational pharmacogenomics program incorporating in-vitro experimental therapeutic models 
• International pharmacotherapy education and research initiative
• Efficient system with industry-standard quality assurance and operating procedures
• Data management and data analysis provided in conjunction with the Center for Computational Research
• Links with facilities throughout the UB Clinical and Translational Research Center and National Center for Ontological Research